Clinical Trial Detail

NCT ID NCT03872505
Title Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (PANDoRA)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Cedars-Sinai Medical Center
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + Durvalumab + Paclitaxel

Age Groups: senior adult

Additional content available in CKB BOOST